查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1916941

银屑病生物相似药市场按产品类型、给药途径、分销管道和最终用户划分－2026-2032年全球预测

Psoriasis Biosimilar Market by Product Type, Route Of Administration, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，干癣生物类似药市场价值将达到 89.7 亿美元，到 2026 年将成长至 97.4 亿美元，到 2032 年将达到 188.8 亿美元，复合年增长率为 11.22%。

关键市场统计数据
基准年 2025 89.7亿美元
预计年份：2026年 97.4亿美元
预测年份 2032 188.8亿美元
复合年增长率 (%) 11.22%

本文全面概述了当前科学、监管和商业性趋势如何重塑银屑病生物相似药市场，以及对相关人员策略的实际影响。

银屑病生物相似药的市场环境正处于一个转折点，科学成熟度、监管发展和商业性趋势的转变交织在一起，为生产商、支付方、医疗服务提供者和患者带来了机会和风险。分析表征、生产製程控制和真实世界证据的进步，增强了临床医生和监管机构对生物相似药疗法的信心，他们相信生物相似药疗法能够复製原研生物製药的临床疗效，同时为长期疾病管理提供更具竞争力的选择。同时，支付方和采购机构正在改进合约评估方式，以评估已证实的治疗等效性和成本效益，并将产品差异化置于单价之外的策略重点。

在整个银屑病生物相似药生态系统中，推动治疗可及性、生产灵活性和竞争差异化的变革需要综合策略应对。

过去几年，变革性的变化重新定义了银屑病生物相似药的研发、核准和应用方式。调查方法和过程分析技术的进步降低了免疫抗原性和结构可比性的不确定性，使许多地区的临床试验得以缩短，并提高了跨适应症外推的可行性。同时，法规结构日趋成熟，监管机构更加重视健全的药物监测、可追溯性和核准后证据的生成。这促使业界加大对真实世界资料系统和病患登记系统的投入，以证明药物的长期安全性和有效性。

评估美国2025年实施的累积关税变化及其对供应链韧性、价格谈判和策略性製造选择的多方面影响

美国将于2025年实施的新关税政策，为银屑病生物相似药领域的企业带来了一系列重要的营运和商业考量。关税调整会影响国际供应链的经济效益，改变活性药物成分、生物製药和成品的采购和生产地点奖励。对于依赖跨境原料流动或第三方生产的开发商而言，关税政策凸显了供应链图谱绘製、剂量成本敏感性分析以及与合约研发生产机构（CDMO）签订合约保障措施的重要性。因此，许多企业正在加速在地化策略的实施，并实现供应链多元化，以降低单一国家贸易中断的风险。

针对特定细分市场的洞察分析揭示了产品类型、给药途径、分销管道和最终用户特征如何决定生物相似药的采用模式和临床应用。

在干癣生物类似药领域，细分市场的特定趋势塑造了产品推广路径和竞争重点，而产品类型的差异决定了临床定位和研发重点。此领域可细分为融合蛋白和单株抗体两大类。融合蛋白类包括Etanercept生物相似药，而单株抗体类包括Adalimumab单抗生物相似药和Infliximab单抗生物相似药。每类产品都面临独特的生产挑战和推广应用的考量，这些都会影响监管策略和临床医生的信心。给药途径也是一个重要因素，静脉注射和皮下注射在供应链需求、病患支持需求和医护人员培训需求方面存在差异。静脉注射製剂通常与医院输液服务相匹配，其低温运输和给药成本与皮下注射製剂不同，后者更适合社区和居家医疗。

区域观点：分析美洲、欧洲、中东和非洲以及亚太地区的需求驱动因素、报销架构和基础设施差异。

区域在报销、监管实践和医疗基础设施方面的差异对银屑病生物相似药的推广和规模有显着影响。在美洲，从单一支付方的州级体係到公私混合市场，各医疗体系的差异化要求采取不同的支付方参与策略、竞标方式和临床医生教育，以支持生物类似药的推广应用。在欧洲、中东和非洲，虽然部分地区的生物相似药核准途径法规环境较为统一，但在其他地区，准入挑战和采购方式的差异依然存在，因此区域伙伴关係和本地市场证据的收集是成功策略的关键要素。在亚太地区，区域客製化的临床数据和患者支援模式日益重要，这反映了该地区法规结构的多样性和快速发展、多个国家强大的国内生产能力以及不同的报销和分销基础设施。

开发商、製造商和专业经销商之间的竞争格局和联盟考量，正在塑造银屑病生物类似药的竞争格局和市场进入趋势。

银屑病生物相似药领域的竞争格局由成熟的生物製药生产商、专业的生物相似药开发商、契约製造生产商和分销商组成。领先企业凭藉其生产规模、成熟的监管能力以及在上市后核准建立方面的投入脱颖而出，从而赢得医疗服务提供者和支付方的信任。策略联盟、授权协议和共同开发契约十分常见，这些协议能够实现技术转移、本地市场准入和共用商业基础设施，从而加快产品上市速度并降低单一方承担的监管风险。合约开发和生产组织 (CDMO) 在产能扩张和风险分担方面发挥关键作用，它们提供模组化能力以支援快速上市和灵活的供应承诺。

在生物相似药时代变革中，为产业领导者提供切实可行的建议，以协调研发实力、生产韧性、商业性差异化和支付方合作。

产业领导者应优先考虑一系列整合科学可信度、商业性可行性和营运韧性的措施。首先，投资于严谨的可比较性资料包和核准后证据生成，以明确解决临床医生和支付方对安全性、可替代性和长期疗效的担忧。其次，设计以灵活的生产能力、区域中心和双重采购为重点的生产策略，以确保供应稳定，同时减轻贸易政策波动和关税相关成本压力的影响。第三，采用差异化的商业模式，将具有竞争力的价格与附加价值服务（例如病患支援、依从性计画和疗效监测）结合，从而将支付方的关注点从单位成本转移到总医疗成本。

调查方法和资料来源的透明度，包括对基础资料来源、分析框架、检验程序以及银屑病生物类似药策略分析限制的解释

本分析采用三角验证研究途径，整合多面向证据，旨在确保其可靠性和实际应用价值。调查方法包括：系统性回顾监管指南、同行评审的生物製药可比性和免疫抗原性文献、分析公开文件和采购机制，以及与临床、生产和市场进入专家进行结构化访谈，以验证检验并识别执行风险。数据综合分析着重探讨不同司法管辖区的监管趋势、生产和供应链的实际情况，以及商业性实施的经验性见解，从而确定能够显着影响推广率和市场韧性的策略槓桿。

总结而言，本文对银屑病生物相似药在科学、监管、分销和患者获取方面的新兴趋势进行了综合分析，并探讨了其对相关人员。

总之，银屑病生物相似药市场正从概念验证阶段迈向营运卓越、策略伙伴关係和实证商业模式将决定其持续成功的阶段。儘管科学和监管方面的进步降低了准入门槛，但市场接受度仍然不均衡，并将取决于企业能否将生产可靠性、区域市场进入计划和核准后证据整合到一个连贯的价值提案中。贸易政策和关税的变化带来了额外的营运复杂性，凸显了灵活的生产和供应链策略的重要性。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 银屑病生物相似药市场（依产品类型划分）

  • 融合蛋白
  • 单株抗体
    • Adalimumab生物相似药
    • Infliximab生物类似药

9. 银屑病生物相似药市场依给药途径划分

  • 静脉注射
  • 皮下注射

10. 银屑病生物相似药市场（依分销管道划分）

  • 医院药房
  • 网路药房
  • 零售药房

第十一章 银屑病生物相似药市场（依最终用户划分）

  • 诊所
  • 医院
  • 专业皮肤病中心

12. 银屑病生物相似药市场（按地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 银屑病生物相似药市场（依类别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 各国银屑病生物相似药市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章美国银屑病生物相似药市场

第十六章：中国银屑病生物相似药市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Amgen Inc.
  • Biocon Ltd.
  • Boehringer Ingelheim International GmbH
  • Celltrion, Inc.
  • Coherus BioSciences, Inc.
  • Fresenius Kabi
  • Pfizer Inc.
  • Samsung Bioepis Co., Ltd.
  • Sandoz International GmbH
  • Stada Arzneimittel AG
  • Viatris, Inc.
Product Code: MRR-AE420CB1540B

The Psoriasis Biosimilar Market was valued at USD 8.97 billion in 2025 and is projected to grow to USD 9.74 billion in 2026, with a CAGR of 11.22%, reaching USD 18.88 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 8.97 billion
Estimated Year [2026] USD 9.74 billion
Forecast Year [2032] USD 18.88 billion
CAGR (%) 11.22%

A comprehensive introduction outlining the current scientific, regulatory, and commercial dynamics reshaping psoriasis biosimilars and practical implications for stakeholder strategies

The psoriasis biosimilar landscape sits at an inflection point where scientific maturity, regulatory evolution, and shifting commercial dynamics intersect to create both risk and opportunity for manufacturers, payers, providers, and patients. Advances in analytical characterization, manufacturing process control, and real-world evidence generation have increased confidence among clinicians and regulators that biosimilar therapies can replicate the clinical performance of originator biologics while offering competitive options for long-term disease management. At the same time, payers and procurement bodies are evolving their contracting approaches to reward demonstrated therapeutic equivalence and cost-effectiveness, which places strategic emphasis on product differentiation beyond unit price.

Operationally, developers must navigate complex biologics manufacturing and supply-chain constraints while aligning clinical development strategies to local regulatory expectations that continue to converge but remain heterogeneous across jurisdictions. Commercial teams are rethinking brand positioning and provider engagement, emphasizing dossier completeness, outcomes data, and patient support mechanisms to accelerate uptake. As stakeholders reassess risk tolerances and investment priorities, clear alignment across R&D, regulatory, manufacturing, and commercial functions becomes essential to convert scientific capability into sustained market access and patient benefit. This introduction frames the analysis that follows, focusing on the practical considerations organizations must address to succeed in this rapidly maturing therapeutic category.

Transformative shifts driving therapeutic access, manufacturing agility, and competitive differentiation across the psoriasis biosimilar ecosystem that demand integrated strategic responses

Over the past several years, transformative shifts have redefined how psoriasis biosimilars are developed, approved, and adopted. Technological advancements in analytical methodologies and process analytics have reduced residual uncertainty around immunogenicity and structural comparability, enabling abbreviated clinical pathways in many jurisdictions and increasing the feasibility of extrapolation across indications. Concurrently, regulatory frameworks have matured, with agencies emphasizing robust pharmacovigilance, traceability, and post-approval evidence generation, which has in turn shaped industry investment into real-world data systems and patient registries to demonstrate long-term safety and effectiveness.

Commercially, competitive differentiation has moved beyond price alone toward evidence-based value propositions that include manufacturing reliability, supply security, patient support services, and outcomes-based contracting. Manufacturing scale-up strategies emphasize flexible facilities and modular process designs to mitigate capacity constraints and accelerate technology transfer. Market access dynamics are also shifting as payers and health systems prioritize therapeutic interchange policies and value-based procurement approaches that reward suppliers capable of delivering measurable clinical and economic outcomes. Taken together, these shifts compel companies to integrate scientific robustness with commercial agility, aligning internal capabilities to navigate complex stakeholder expectations and seize opportunities in a landscape where clinical equivalence must be matched by demonstrable system-level value.

Assessment of cumulative United States tariff changes in 2025 and their multidimensional effects on supply chain resilience, pricing negotiations, and strategic manufacturing choices

The introduction of new tariffs in the United States in 2025 has introduced a material set of operational and commercial considerations for actors in the psoriasis biosimilar arena. Tariff adjustments affect the economics of international supply chains, altering incentives for where active pharmaceutical ingredients, biologics drug substances, and finished products are sourced and manufactured. For developers reliant on cross-border raw material flows or on third-party manufacturing, tariffs increase the importance of supply-chain mapping, cost-per-dose sensitivity analysis, and contractual safeguards with contract development and manufacturing organizations. As a result, many organizations have responded by accelerating localization strategies or diversifying supplier bases to reduce exposure to single-country trade disruptions.

Beyond cost impacts, tariffs have implications for pricing strategy and payer negotiations. Procurement organizations may demand clearer evidence of total cost of care and supply resilience as part of contracting discussions, and manufacturers may need to offer more robust risk-sharing or bundled contracting solutions to maintain formulary access. Clinical trial logistics are also affected where investigational product imports and clinical supplies cross tariff boundaries, necessitating proactive customs planning and regulatory filings. Finally, trade policy uncertainty has increased the premium on flexible commercial models, including multi-sourcing, regional manufacturing hubs, and enhanced inventory management, all intended to insulate patients and providers from intermittent supply volatility while preserving long-term strategic options.

Segment-specific insights decoding how product types, administration routes, distribution channels, and end-user profiles will determine adoption patterns and clinical uptake for biosimilars

Segment-specific dynamics will shape adoption pathways and competitive focus areas across the psoriasis biosimilar sector, with product-type distinctions driving clinical positioning and development priorities. The landscape differentiates between fusion proteins and monoclonal antibodies, where the fusion proteins segment includes etanercept biosimilars and the monoclonal antibodies segment encompasses adalimumab biosimilars and infliximab biosimilars; each category presents distinct manufacturing control challenges and extrapolation considerations that influence regulatory strategies and clinician confidence. Route of administration is another critical axis, where intravenous administration and subcutaneous administration impose different supply chain requirements, patient support needs, and provider training imperatives; intravenous formulations often align with hospital-based infusion services and have different cold-chain and administration cost profiles compared with subcutaneous options suitable for community or home use.

Distribution channel segmentation further defines commercial execution plans, with hospital pharmacy, online pharmacy, and retail pharmacy each requiring tailored contracting models, patient access programs, and reimbursement approaches. End-user segmentation, spanning clinics, hospitals, and specialty dermatology centers, dictates where education, sample programs, and clinical liaison resources should be concentrated to influence prescribing behavior and optimize continuity of care. Strategic choices around which segments to prioritize will depend on a company's manufacturing footprint, logistical competencies, and commercial channel capabilities, and successful players will align clinical evidence packages, service offerings, and distribution arrangements to the operational realities and decision-making processes of each segment.

Regional perspectives dissecting demand drivers, reimbursement frameworks, and infrastructure variations across the Americas, Europe Middle East & Africa, and Asia-Pacific regions

Regional nuances in reimbursement, regulatory practice, and healthcare infrastructure critically influence how psoriasis biosimilars are introduced and scaled. In the Americas, systems range from single-payer provincial frameworks to mixed public-private markets, requiring differentiated payer engagement strategies, tendering approaches, and clinician education to support biosimilar uptake. In Europe, Middle East & Africa the regulatory environment often exhibits greater harmonization for biosimilar pathways in some subregions while access challenges and procurement variability persist in others, making regional partnerships and local-market evidence generation important components of a successful strategy. Asia-Pacific presents a heterogeneous mix of rapidly evolving regulatory frameworks, strong domestic manufacturing capabilities in several countries, and growing emphasis on localized clinical data and patient-assistance models that reflect varied reimbursement and distribution infrastructures.

Across these geographies, planning for regulatory dossier alignment, pharmacovigilance networks, and supply resilience is essential. Differences in healthcare delivery models and payer levers mean that successful regional strategies combine technical evidence packages with pragmatic commercial models adapted to procurement cycles, clinical practice norms, and the local value discourse. Companies that blend global development consistency with local implementation agility-whether through regional manufacturing hubs, strategic partnerships, or targeted evidence generation-are better positioned to navigate regional complexities and accelerate patient access while maintaining operational control.

Competitive profiling and partnership considerations for developers, manufacturers, and specialty distributors shaping psoriasis biosimilar competition and market entry dynamics

Competitive dynamics in the psoriasis biosimilar space are defined by a mix of established biologics manufacturers, specialized biosimilar developers, contract manufacturers, and distribution specialists. Leading players differentiate through manufacturing scale, demonstrated regulatory track record, and investments in post-approval evidence that build clinician and payer trust. Strategic partnerships, licensing agreements, and co-development arrangements are common, enabling technology transfer, local market entry, and shared commercial infrastructure that reduces time-to-market and mitigates single-party exposure to regulatory risk. Contract development and manufacturing organizations play a crucial role in capacity expansion and risk sharing, offering modular capabilities that support accelerated launches and flexible supply commitments.

Commercial differentiation increasingly relies on integrated service offerings that go beyond the molecule to include patient support programs, injection training, adherence monitoring, and real-world outcome tracking. Specialty distributors and pharmacy networks that can ensure cold-chain integrity and timely delivery to hospital pharmacies, retail outlets, and online fulfillment channels are essential to maintaining clinician confidence. Intellectual property strategies, portfolio breadth across etanercept, adalimumab, and infliximab biosimilars, and a clear record of regulatory approvals also shape competitive positioning. Market entrants that combine robust technical capability with pragmatic commercialization and partnership models tend to achieve greater acceptance in complex procurement environments where evidence of operational reliability and cost of care impact informs payer and provider decisions.

Actionable recommendations for industry leaders to align R&D robustness, manufacturing resilience, commercial differentiation, and payer engagement in a changing biosimilar era

Industry leaders should prioritize an integrated set of actions that align scientific credibility with commercial execution and operational resilience. First, invest in rigorous comparability packages and post-approval evidence generation that demonstrably address clinician and payer concerns about safety, interchangeability, and long-term outcomes. Second, design manufacturing strategies that emphasize flexible capacity, regional hubs, and dual-sourcing to mitigate trade policy shocks and tariff-related cost pressures while ensuring consistent supply. Third, adopt differentiated commercial models that combine competitive pricing with value-added services such as patient support, adherence programs, and outcomes monitoring, thereby shifting conversations with payers from unit price to total cost of care.

Additionally, strengthen payer and provider engagement through early, evidence-driven dialogue and tailored value dossiers that reflect local reimbursement criteria and procurement cycles. Build partnerships with specialty distributors and clinical sites to ensure seamless administration across intravenous and subcutaneous channels, and invest in digital platforms that support remote patient management and data capture. Finally, embed scenario planning into strategic decision-making to anticipate policy and trade changes, and align internal governance to enable rapid reallocation of resources in response to regulatory or supply-chain disruptions. Acting across these dimensions will help organizations convert technical capability into sustained market access and durable clinical adoption.

Methodological transparency explaining data sources, analytical frameworks, validation steps, and limitations that underpin the psoriasis biosimilar strategic analysis

This analysis synthesizes multiple evidence streams using a triangulated research approach designed to ensure reliability and practical relevance. The methodology combined systematic review of regulatory guidance, peer-reviewed literature on biologics comparability and immunogenicity, analysis of public filings and procurement mechanisms, and structured interviews with clinical, manufacturing, and market access experts to validate assumptions and surface execution risks. Data synthesis emphasized cross-jurisdictional regulatory trends, manufacturing and supply-chain realities, and experiential insights from commercial launches to identify strategic levers that materially affect uptake and resilience.

Validation steps included iterative review with subject-matter experts, scenario testing of supply-chain and tariff sensitivities, and cross-checking of claims against regulatory guidance documents and clinical evidence where available. Limitations of the methodology are acknowledged: evolving regulatory policies and trade measures can change the operating environment after publication, and some proprietary commercial data was not accessible for confidentiality reasons. To mitigate these constraints, the report focuses on actionable qualitative insights and decision frameworks rather than numerical market projections, enabling readers to apply the findings to their own internal data and strategic plans.

Concluding synthesis tying strategic implications for stakeholders to emergent trends in science, regulation, distribution, and patient access for psoriasis biosimilars

In conclusion, the psoriasis biosimilar landscape is transitioning from a proof-of-concept era into a phase where operational excellence, strategic partnerships, and evidence-based commercial models determine sustainable success. Scientific and regulatory progress has lowered barriers to entry, but adoption will be uneven and driven by an organization's ability to integrate manufacturing reliability, localized market access planning, and post-approval evidence into a coherent value proposition. Trade policies and tariff changes introduce additional operational complexity that elevates the importance of flexible manufacturing and supply-chain strategies.

Stakeholders who proactively align internal capabilities-spanning comparability science, scalable manufacturing, payer engagement, and patient support-will be positioned to convert technical equivalence into meaningful clinical and economic outcomes. The path forward emphasizes disciplined execution, adaptive commercial models, and investment in evidence generation that resonates with clinicians and payers. Ultimately, success in this therapeutic segment will rest on the ability to deliver consistent clinical performance at scale while addressing the systemic levers that influence access and long-term adoption.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Psoriasis Biosimilar Market, by Product Type

  • 8.1. Fusion Proteins
  • 8.2. Monoclonal Antibodies
    • 8.2.1. Adalimumab Biosimilars
    • 8.2.2. Infliximab Biosimilars

9. Psoriasis Biosimilar Market, by Route Of Administration

  • 9.1. Intravenous Administration
  • 9.2. Subcutaneous Administration

10. Psoriasis Biosimilar Market, by Distribution Channel

  • 10.1. Hospital Pharmacy
  • 10.2. Online Pharmacy
  • 10.3. Retail Pharmacy

11. Psoriasis Biosimilar Market, by End User

  • 11.1. Clinics
  • 11.2. Hospitals
  • 11.3. Specialty Dermatology Centers

12. Psoriasis Biosimilar Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Psoriasis Biosimilar Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Psoriasis Biosimilar Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Psoriasis Biosimilar Market

16. China Psoriasis Biosimilar Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Amgen Inc.
  • 17.6. Biocon Ltd.
  • 17.7. Boehringer Ingelheim International GmbH
  • 17.8. Celltrion, Inc.
  • 17.9. Coherus BioSciences, Inc.
  • 17.10. Fresenius Kabi
  • 17.11. Pfizer Inc.
  • 17.12. Samsung Bioepis Co., Ltd.
  • 17.13. Sandoz International GmbH
  • 17.14. Stada Arzneimittel AG
  • 17.15. Viatris, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PSORIASIS BIOSIMILAR MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PSORIASIS BIOSIMILAR MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES PSORIASIS BIOSIMILAR MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA PSORIASIS BIOSIMILAR MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY FUSION PROTEINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY FUSION PROTEINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY FUSION PROTEINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY ADALIMUMAB BIOSIMILARS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY ADALIMUMAB BIOSIMILARS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY ADALIMUMAB BIOSIMILARS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY INFLIXIMAB BIOSIMILARS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY INFLIXIMAB BIOSIMILARS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY INFLIXIMAB BIOSIMILARS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY INTRAVENOUS ADMINISTRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY INTRAVENOUS ADMINISTRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY INTRAVENOUS ADMINISTRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY SUBCUTANEOUS ADMINISTRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY SUBCUTANEOUS ADMINISTRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY SPECIALTY DERMATOLOGY CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY SPECIALTY DERMATOLOGY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY SPECIALTY DERMATOLOGY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. AMERICAS PSORIASIS BIOSIMILAR MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 45. AMERICAS PSORIASIS BIOSIMILAR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 46. AMERICAS PSORIASIS BIOSIMILAR MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 47. AMERICAS PSORIASIS BIOSIMILAR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 48. AMERICAS PSORIASIS BIOSIMILAR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 49. AMERICAS PSORIASIS BIOSIMILAR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 50. NORTH AMERICA PSORIASIS BIOSIMILAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. NORTH AMERICA PSORIASIS BIOSIMILAR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 52. NORTH AMERICA PSORIASIS BIOSIMILAR MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 53. NORTH AMERICA PSORIASIS BIOSIMILAR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 54. NORTH AMERICA PSORIASIS BIOSIMILAR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 55. NORTH AMERICA PSORIASIS BIOSIMILAR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 56. LATIN AMERICA PSORIASIS BIOSIMILAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. LATIN AMERICA PSORIASIS BIOSIMILAR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 58. LATIN AMERICA PSORIASIS BIOSIMILAR MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 59. LATIN AMERICA PSORIASIS BIOSIMILAR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 60. LATIN AMERICA PSORIASIS BIOSIMILAR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 61. LATIN AMERICA PSORIASIS BIOSIMILAR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 62. EUROPE, MIDDLE EAST & AFRICA PSORIASIS BIOSIMILAR MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 63. EUROPE, MIDDLE EAST & AFRICA PSORIASIS BIOSIMILAR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 64. EUROPE, MIDDLE EAST & AFRICA PSORIASIS BIOSIMILAR MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 65. EUROPE, MIDDLE EAST & AFRICA PSORIASIS BIOSIMILAR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 66. EUROPE, MIDDLE EAST & AFRICA PSORIASIS BIOSIMILAR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 67. EUROPE, MIDDLE EAST & AFRICA PSORIASIS BIOSIMILAR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 68. EUROPE PSORIASIS BIOSIMILAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPE PSORIASIS BIOSIMILAR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE PSORIASIS BIOSIMILAR MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE PSORIASIS BIOSIMILAR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE PSORIASIS BIOSIMILAR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE PSORIASIS BIOSIMILAR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 74. MIDDLE EAST PSORIASIS BIOSIMILAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. MIDDLE EAST PSORIASIS BIOSIMILAR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. MIDDLE EAST PSORIASIS BIOSIMILAR MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 77. MIDDLE EAST PSORIASIS BIOSIMILAR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 78. MIDDLE EAST PSORIASIS BIOSIMILAR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 79. MIDDLE EAST PSORIASIS BIOSIMILAR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. AFRICA PSORIASIS BIOSIMILAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. AFRICA PSORIASIS BIOSIMILAR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. AFRICA PSORIASIS BIOSIMILAR MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 83. AFRICA PSORIASIS BIOSIMILAR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 84. AFRICA PSORIASIS BIOSIMILAR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 85. AFRICA PSORIASIS BIOSIMILAR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC PSORIASIS BIOSIMILAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC PSORIASIS BIOSIMILAR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC PSORIASIS BIOSIMILAR MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC PSORIASIS BIOSIMILAR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC PSORIASIS BIOSIMILAR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC PSORIASIS BIOSIMILAR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. ASEAN PSORIASIS BIOSIMILAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. ASEAN PSORIASIS BIOSIMILAR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. ASEAN PSORIASIS BIOSIMILAR MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 96. ASEAN PSORIASIS BIOSIMILAR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 97. ASEAN PSORIASIS BIOSIMILAR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. ASEAN PSORIASIS BIOSIMILAR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. GCC PSORIASIS BIOSIMILAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GCC PSORIASIS BIOSIMILAR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. GCC PSORIASIS BIOSIMILAR MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 102. GCC PSORIASIS BIOSIMILAR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 103. GCC PSORIASIS BIOSIMILAR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 104. GCC PSORIASIS BIOSIMILAR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPEAN UNION PSORIASIS BIOSIMILAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPEAN UNION PSORIASIS BIOSIMILAR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPEAN UNION PSORIASIS BIOSIMILAR MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPEAN UNION PSORIASIS BIOSIMILAR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPEAN UNION PSORIASIS BIOSIMILAR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPEAN UNION PSORIASIS BIOSIMILAR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. BRICS PSORIASIS BIOSIMILAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. BRICS PSORIASIS BIOSIMILAR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. BRICS PSORIASIS BIOSIMILAR MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 114. BRICS PSORIASIS BIOSIMILAR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 115. BRICS PSORIASIS BIOSIMILAR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 116. BRICS PSORIASIS BIOSIMILAR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. G7 PSORIASIS BIOSIMILAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. G7 PSORIASIS BIOSIMILAR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. G7 PSORIASIS BIOSIMILAR MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 120. G7 PSORIASIS BIOSIMILAR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 121. G7 PSORIASIS BIOSIMILAR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 122. G7 PSORIASIS BIOSIMILAR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. NATO PSORIASIS BIOSIMILAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. NATO PSORIASIS BIOSIMILAR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. NATO PSORIASIS BIOSIMILAR MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 126. NATO PSORIASIS BIOSIMILAR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 127. NATO PSORIASIS BIOSIMILAR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. NATO PSORIASIS BIOSIMILAR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. UNITED STATES PSORIASIS BIOSIMILAR MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 131. UNITED STATES PSORIASIS BIOSIMILAR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. UNITED STATES PSORIASIS BIOSIMILAR MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 133. UNITED STATES PSORIASIS BIOSIMILAR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 134. UNITED STATES PSORIASIS BIOSIMILAR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 135. UNITED STATES PSORIASIS BIOSIMILAR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. CHINA PSORIASIS BIOSIMILAR MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 137. CHINA PSORIASIS BIOSIMILAR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. CHINA PSORIASIS BIOSIMILAR MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 139. CHINA PSORIASIS BIOSIMILAR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 140. CHINA PSORIASIS BIOSIMILAR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. CHINA PSORIASIS BIOSIMILAR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)